The year in electrophysiology

Journal of the American College of Cardiology

Volumn 43, Issue 7, 2004, Pages 1306-1314

  Zipes, Douglas P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POTASSIUM CHANNEL BLOCKING AGENT; SPIRONOLACTONE; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ARTIFICIAL HEART PACEMAKER; BRUGADA SYNDROME; CATHETER ABLATION; CLINICAL TRIAL; GENETIC ANALYSIS; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART FUNCTION TEST; HEART TAMPONADE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; NONHUMAN; PRIORITY JOURNAL; PULMONARY VEIN OBSTRUCTION; REVIEW; SINUS NODE; THROMBOGENESIS;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CATHETER ABLATION; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE, CONGESTIVE; HEART-ASSIST DEVICES; HUMANS;

EID: 1842582766     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.01.027     Document Type: Review

References (97)

1. Das M, Zipes DP. History of thoracic vein arrhythmias: pulmonary veins and vena cavae. In: Chen SA, Haissaguerre M, Zipes DP, editors. Electrophysiology of the Thoracic Veins. Blackwell Publishing, 2004. In Press
2. Haissaguerre M., Jais P., Shah D.C., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 339:1998;659-666.
3. Jais P., Hocini M., Macle L., et al. Distinctive electrophysiological properties of pulmonary veins in patients with atrial fibrillation. Circulation. 106:2002;2479-2485.
4. Kato R., Lickfett L., Meininger G., et al. Pulmonary vein anatomy in patients undergoing catheter ablation of atrial fibrillation lessons learned by use of magnetic resonance imaging. Circulation. 107:2003;2004-2010.
5. Schwartzman D., Lacomis J., Wigginton W.G. Characterization of left atrium and distal pulmonary vein morphology using multidimensional computed tomography. J Am Coll Cardiol. 41:2003;1349-1357.
6. Kistler P.M., Sanders P., Fynn S.P., et al. Electrophysiological and electrocardiographic characteristics of focal atrial tachycardia originating from the pulmonary veins acute and long-term outcomes of radiofrequency ablation. Circulation. 108:2003;1968-1975.
7. Burashnikov A., Antzelevitch C. Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation. 107:2003;2355-2360.
8. Arora R., Verheule S., Scott L., et al. Arrhythmogenic substrate of the pulmonary veins assessed by high-resolution optical mapping. Circulation. 107:2003;1816-1821.
9. Lin W.S., Tai C.T., Hsieh M.H., et al. Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy. Circulation. 107:2003;3176-3183.
10. Jalife J. Rotors and spiral waves in atrial fibrillation. J Cardiovasc Electrophysiol. 14:2003;776-780.
11. Ausma J., van der Velden H.M., Lenders M.H., et al. Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat. Circulation. 107:2003;2051-2058.
12. Elvan A., Wylie K., Zipes D.P. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs. Electrophysiological remodeling. Circulation. 94:1996;2953-2960.
13. Hocini M., Sanders P., Deisenhofer I., et al. Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses. Circulation. 108:2003;1172-1175.
14. Satoh T., Zipes D.P. Cesium-induced atrial tachycardia degenerating into atrial fibrillation in dogs atrial torsades de pointes? J Cardiovasc Electrophysiol. 9:1998;970-975.
15. Kirchhof P., Eckardt L., Franz M.R., et al. Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol. 14:2003;1027-1033.
16. Nakamura Y., Nakamura K., Fukushima-Kusano K., et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation possible involvement in intracardiac thrombogenesis. Thromb Res. 111:2003;137-142.
17. Chen P.S., Wu T.J., Ting C.T., et al. A tale of two fibrillations. Circulation. 108:2003;2298-2303.
18. Garfinkel A., Kim Y.H., Voroshilovsky O., et al. Preventing ventricular fibrillation by flattening cardiac restitution. Proc Natl Acad Sci U S A. 97:2000;6061-6066.
19. Taggart P., Sutton P., Chalabi Z., et al. Effect of adrenergic stimulation on action potential duration restitution in humans. Circulation. 107:2003;285-289.
20. Samie F.H., Berenfeld O., Anumonwo J., et al. Rectification of the background potassium current a determinant of rotor dynamics in ventricular fibrillation. Circ Res. 89:2001;1216-1223.
21. The Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure meta-analysis of individual data from 6500 patients in randomised trials. Lancet. 350:1997;1417-1424.
22. Alberte C., Zipes D.P. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J Cardiovasc Electrophysiol. 14:2003;S87-95.
23. Liu Y.B., Wu C.C., Lu L.S., et al. Sympathetic nerve sprouting, electrical remodeling, and increased vulnerability to ventricular fibrillation in hypercholesterolemic rabbits. Circ Res. 92:2003;1145-1152.
24. Mitchell L.B., Powell J.L., Gillis A.M., et al. Are lipid-lowering drugs also antiarrhythmic drugs?An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol. 42:2003;81-87.
25. Antzelevitch C. Molecular genetics of arrhythmias and cardiovascular conditions associated with arrhythmias. J Cardiovasc Electrophysiol. 14:2003;1259-1272.
26. Pitzalis M.V., Anaclerio M., Iacoviello M., et al. QT-interval prolongation in right precordial leads an additional electrocardiographic hallmark of Brugada syndrome. J Am Coll Cardiol. 42:2003;1632-1637.
27. Morita H., Morita S.T., Nagase S., et al. Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol. 42:2003;1624-1631.
28. George C.H., Higgs G.V., Lai F.A. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res. 93:2003;531-540.
29. Tabib A., Loire R., Chalabreysse L., et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation. 108:2003;3000-3005.
30. Link M.S., Maron B.J., Wang P.J., et al. Upper and lower limits of vulnerability to sudden arrhythmic death with chest-wall impact (commotio cordis). J Am Coll Cardiol. 41:2003;99-104.
31. Keating M., Atkinson D., Dunn C., et al. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science. 252:1991;704-706.
32. Priori S.G., Napolitano C., Vicentini A. Inherited arrhythmia syndromes applying the molecular biology and genetic to the clinical management. J Interv Card Electrophysiol. 9:2003;93-101.
33. Mohler P.J., Schott J.J., Gramolini A.O., et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature. 421:2003;634-639.
34. Zareba W., Moss A.J., Sheu G., et al. Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome. J Cardiovasc Electrophysiol. 14:2003;1149-1153.
35. Shimizu W., Noda T., Takaki H., et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long QT syndrome. J Am Coll Cardiol. 41:2003;633-642.
36. Priori S.G., Schwartz P.J., Napolitano C., et al. Risk stratification in the long QT syndrome. N Engl J Med. 348:2003;1866-1874.
37. Veldkamp M.W., Wilders R., Baartscheer A., et al. Contribution of sodium channel mutations to bradycardia and sinus node dysfunction in LQT3 families. Circ Res. 92:2003;976-983.
38. Fukada Y., Miyoshi S., Tanimoto K., et al. Autoimmunity against the second extracellular loop of B1 adrenergic receptors induces early afterdepolarization and decreases in K-channel density in rabbits (abstr). Pacing Clin Electrophysiol. 26:2003;1085.
39. Katayama Y., Haraoka K., Tani M., et al. Serum from an acquired long QT syndrome patient reduced rapid component of the cardiac delayed rectifier K+ current (abstr). Pacing Clin Electrophysiol. 26:2003;1022.
40. Brunner M., Kodirov S.A., Mitchell G.F., et al. In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype. Am J Physiol Heart Circ Physiol. 285:2003;H194-203.
41. Brugada R., Hong K., Dumaine R., et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation. 109:2004;30-35.
42. Gaita F., Giustetto C., Bianchi F., et al. Short QT syndrome a familial cause of sudden death. Circulation. 108:2003;965-970.
43. Plaster N.M., Tawil R., Tristani-Firouzi M., et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Anderse's syndrome. Cell. 105:2001;511-519.
44. Brugada J., Brugada R., Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation. 108:2003;3092-3096.
45. Brugada P., Brugada R., Mont L., et al. Natural history of Brugada syndrome the prognostic value of programmed electrical stimulation of the heart. J Cardiovasc Electrophysiol. 14:2003;455-457.
46. Mok N.S., Priori S.G., Napolitano C., et al. A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia. J Cardiovasc Electrophysiol. 14:2003;407-411.
47. Wehrens X.H., Lehnart S.E., Huang F., et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell. 113:2003;829-840.
48. Wehrens X.H., Marks A.R. Altered function and regulation of cardiac ryanodine receptors in cardiac disease. Trends Biochem Sci. 28:2003;671-678.
49. Laitinen P.J., Swan H., Kontula K. Molecular genetics of exercise-induced polymorphic ventricular tachycardia identification of three novel cardiac ryanodine receptor mutations and two common calsequestrin 2 amino-acid polymorphisms. Eur J Hum Genet. 11:2003;888-891.
50. Sumitomo N., Harada K., Nagashima M., et al. Catecholaminergic polymorphic ventricular tachycardia electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 89:2003;66-70.
51. Chen Y.H., Xu S.J., Bendahhou S., et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science. 299:2003;251-254.
52. Lai L.P., Lin J.L., Huang S.K. Molecular genetic studies in atrial fibrillation. Cardiology. 100:2003;109-113.
53. Probst V., Kyndt F., Potet F., et al. Haploinsufficiency in combination with aging causes SCN5A-linked hereditary Lenegre disease. J Am Coll Cardiol. 41:2003;643-652.
54. Groenewegen W.A., Firouzi M., Bezzina C.R., et al. A cardiac sodium channel mutation cosegregates with a rare connexin40 genotype in familial atrial standstill. Circ Res. 92:2003;14-22.
55. Bezzina C.R., Rook M.B., Groenewegen W.A., et al. Compound heterozygosity for mutations (W156X and R225W) in SCN5A associated with severe cardiac conduction disturbances and degenerative changes in the conduction system. Circ Res. 92:2003;159-168.
56. Rampazzo A., Beffagna G., Nava A., et al. Arrhythmogenic right ventricular cardiomyopathy type 1 (ARVD1) confirmation of locus assignment and mutation screening of four candidate genes. Eur J Hum Genet. 11:2003;69-76.
57. Hamid M.S., Norman M., Quraishi A., et al. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/ dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol. 40:2002;1445-1450.
58. Narin N., Akcakus M., Gunes T., et al. Arrhythmogenic right ventricular cardiomyopathy (Naxos disease). Pacing Clin Electrophysiol. 26:2003;2326-2329.
59. Protonotarios N., Tsatsopoulou A., Anastasakis A., et al. Genotype-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (Naxos disease) caused by a deletion in plakoglobin. J Am Coll Cardiol. 38:2001;1477-1484.
60. Patel V.V., Arad M., Moskowitz I.P., et al. Electrophysiologic characterization and postnatal development of ventricular pre-excitation in a mouse model of cardiac hypertrophy and Wolff-Parkinson-White syndrome. J Am Coll Cardiol. 42:2003;942-951.
61. Gollob M.H., Green M.S., Tang A.S., et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med. 344:2001;1823-1831.
62. Vaughan C.J., Hom Y., Okin D.A., et al. Molecular genetic analysis of PRKAG2 in sporadic Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol. 14:2003;263-268.
63. Morady F. Catheter ablation of supraventricular arrhythmias state of the art. Pacing Clin Electrophysiol. 27:2004;125-142.
64. Pappone C., Rosanio S., Augello G., et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol. 42:2003;185-197.
65. Oral H., Scharf C., Chugh A., et al. Catheter ablation for paroxysmal atrial fibrillation segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation. 108:2003;2355-2360.
66. Dill T., Neumann T., Ekinci O., et al. Pulmonary vein diameter reduction after radiofrequency catheter ablation for paroxysmal atrial fibrillation evaluated by contrast-enhanced three-dimensional magnetic resonance imaging. Circulation. 107:2003;845-850.
67. Pappone C., Santinelli V., Manguso F., et al. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N Engl J Med. 349:2003;1803-1811.
68. Pappone C., Santinelli V., Rosanio S., et al. Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic events in asymptomatic patients with Wolff-Parkinson-White pattern results from a large prospective long-term follow-up study. J Am Coll Cardiol. 41:2003;239-244.
69. Faddis M.N., Lindsay B.D. Magnetic catheter manipulation. Coron Artery Dis. 14:2003;25-27.
70. Schneider M.A., Ndrepepa G., Dobran I., et al. LocaLisa catheter navigation reduces fluoroscopy time and dosage in ablation of atrial flutter a prospective randomized study. J Cardiovasc Electrophysiol. 14:2003;587-590.
71. Dickfeld T., Calkins H., Zviman M., et al. Anatomic stereotactic catheter ablation on three-dimensional magnetic resonance images in real time. Circulation. 108:2003;2407-2413.
72. Doll N., Kiaii B.B., Fabricius A.M., et al. Intraoperative left atrial ablation (for atrial fibrillation) using a new argon cryocatheter early clinical experience. Ann Thorac Surg. 76:2003;1711-1715.
73. Bansch D., Oyang F., Antz M., et al. Successful catheter ablation of electrical storm after myocardial infarction. Circulation. 108:2003;3011-3016.
74. Haissaguerre M., Extramiana F., Hocini M., et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation. 108:2003;925-928.
75. Ouyang F., Antz M., Deger F.T., et al. An underrecognized subepicardial re-entrant ventricular tachycardia attributable to left ventricular aneurysm in patients with normal coronary arteriograms. Circulation. 107:2003;2702-2709.
76. Schweikert R.A., Saliba W.I., Tomassoni G., et al. Percutaneous pericardial instrumentation for endo-epicardial mapping of previously failed ablations. Circulation. 108:2003;1329-1335.
77. Lee D.S., Green L.D., Liu P.P., et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death a meta-analysis. J Am Coll Cardiol. 41:2003;1573-1582.
78. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 346:2002;877-883.
79. Wilkoff B.L., Cook J.R., Epstein A.E., et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator the Dual Chamber and VVI Implantable Defibrillator (DAVID) trial. JAMA. 288:2002;3115-3123.
80. Nademanee K., Veerakul G., Mower M., et al. Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT) a randomized clinical trial. Circulation. 107:2003;2221-2226.
81. Zareba W., Moss A.J., Daubert J.P., et al. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 14:2003;337-341.
82. Corrado D., Leoni L., Link M.S., et al. Implantable cardioverter- defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 108:2003;3084-3091.
83. Maron B.J., Estes N.A. 3rd, Maron M.S., et al. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation. 107:2003;2872-2875.
84. Hohnloser S.H., Ikeda T., Bloomfield D.M., et al. T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation. Lancet. 362:2003;125-126.
85. Hohnloser S.H., Klingenheben T., Bloomfield D., et al. Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy results from a prospective observational study. J Am Coll Cardiol. 41:2003;2220-2224.
86. Strickberger S.A., Hummel J.D., Bartlett T.G., et al. Amiodarone versus implantable cardioverter-defibrillator randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol. 41:2003;1707-1712.
87. Ornato J.P., McBurnie M.A., Nichol G., et al. The Public Access Defibrillation (PAD) trial study design and rationale. Resuscitation. 56:2003;135-147.
88. Bunch T.J., White R.D., Gersh B.J., et al. Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation. N Engl J Med. 348:2003;2626-2633.
89. Wirth K.J., Paehler T., Rosenstein B., et al. Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs. Cardiovasc Res. 60:2003;298-306.
90. Roden D. Antiarrhythmic drugs, past, present and future. J Cardiovasc Electrophysiol. 14:2003;1389-1396.
91. Halperin HR. Stroke Prevention Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF-III) trial. Presented at 2003 AHA Scientific Sessions. Circulation 2004. In press
92. Young J.B., Abraham W.T., Smith A.L., et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure the MIRACLE ICD trial. JAMA. 289:2003;2685-2694.
93. Bristow MR, Saxon LA, Bochmer JP, et al. Cardiac resynchronization therapy reduces hospitalization and cardiac resynchronization therapy and an implantable defibrillator reduces mortality in chronic heart failure: results of the COMPANION Trial. Presented at the 2003 ACC Annual Scientific Sessions, Chicago, Illinois
94. St John Sutton M.G., Plappert T., Abraham W.T., et al. Effect of cardiacresynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 107:2003;1985-1990.
95. Medina-Ravell V.A., Lankipalli R.S., Yan G.X., et al. Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes? Circulation. 107:2003;740-746.
96. Guerra J.M., Wu J., Miller J.M., et al. Increase in ventricular tachycardia frequency after biventricular implantable cardioverter defibrillator upgrade. J Cardiovasc Electrophysiol. 14:2003;1245-1247.
97. Pappone C, Augello G, Rosanio S, et al. First human chronic experience with cardiac contractility modulation by non-excitatory electrical currents for treating systolic heart failure. J Cardiovasc Electrophysiol 2004. In Press